The U.S. Blood System: Under Pressure
Dr. Menitove discusses obstacles and pressure on U.S. blood centers and the U.S. blood supply.
Targeted Therapy to Trigger GVL: A Case for the Prosecution in FLT3-ITD–Mutant AML
Dr. Roberts sheds light on a mechanism by which a small molecule inhibitor targeting a leukemia-specific kinase mutation can trigger an effective CD8 T cell-mediated allo-i
Patients with de novo acute myeloid leukemia (AML) typically come to clinical attention with symptoms of bone marrow failure in the absence of any prior hematologic condition. In many such patients, the diagnosis is sudden and unexpected, without any significant prodrome. The generally poor prognosis of AML and the decades-long impasse in generating effective therapeutic strategies other than conventional antracycline and cytarabine-based (“3+7”) induction chemotherapy has spurred intense investigation of its molecular and cellular origins. Pioneering work by numerous investigators led to an early understanding of the genetics of AML, particularly the identification of recurrent chromosomal abnormalities and mutations in the genes FLT3 and NPM1. However, it is only with the recent implementation of massively parallel next-generation DNA sequencing that the full spectrum of mutations in AML has been defined.
May-June 2018Volume 15, Issue 3
A new Compendium providing updated clinical information to "Ask the Hematologist" articles published in The Hematologist from 2010 to 2015 is now available.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology